Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus pioglitazone for non-alcoholic fatty liver disease in adults with type 2 diabetes on metformin
IRCT20220928056051N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Pioglitazone + metformin with Empagliflozin + metformin (2 arms). Primary endpoints: Liver steatosis score, Alanine transaminase and 2 more. Started Jul 2022; status: completed.
02
Drugs
empagliflozinpioglitazone
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20220928056051N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220928056051N1.